Aerosolized Amikacin as Adjunctive Therapy of Ventilator-associated Pneumonia Caused by Multidrug-resistant Gram-negative Bacteria: A Single-center Randomized Controlled Trial

BACKGROUND: Aerosolized amikacin (AA) is a current option for the management of ventilator-associated pneumonia (VAP) caused by multidrug-resistant Gram-negative bacteria (MDR-GNB), as it is reported that AA could increase the alveolar level of the drug without increasing systemic toxicity. This stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Chang, Zhang, Yu-Ting, Peng, Zhi-Yong, Zhou, Qing, Hu, Bo, Zhou, Hui, Li, Jian-Guo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5443026/
https://www.ncbi.nlm.nih.gov/pubmed/28485320
http://dx.doi.org/10.4103/0366-6999.205846

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5443026/
https://www.ncbi.nlm.nih.gov/pubmed/28485320
http://dx.doi.org/10.4103/0366-6999.205846

Ejemplares similares